Ofatumumab
Ofatumumab is a monoclonal antibody specifically designed for the treatment of B cell chronic lymphocytic leukemia (CLL). It is a fully human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops.
Mechanism of Action
Ofatumumab binds to the CD20 molecule on B cells, leading to immune-mediated B cell lysis. The CD20 molecule is expressed on more than 90% of B cell CLL. The binding of the antibody to the CD20 molecules induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the lysis of the target cells.
Clinical Use
Ofatumumab is used for the treatment of patients with CLL refractory to fludarabine and alemtuzumab. It is also used in combination with chlorambucil or bendamustine for the treatment of patients with untreated CLL who are not candidates for fludarabine-based therapy.
Side Effects
The most common side effects of ofatumumab include neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infection. Serious side effects include hepatitis B reactivation, progressive multifocal leukoencephalopathy, tumor lysis syndrome, and cytokine release syndrome.
Pharmacokinetics
Ofatumumab is administered intravenously. The pharmacokinetics of ofatumumab have been studied in patients with CLL and follicular lymphoma. The clearance of ofatumumab decreases with increasing doses, and the volume of distribution is approximately equal to the blood volume.
History
Ofatumumab was developed by Genmab and is marketed under the trade name Arzerra. It was approved by the Food and Drug Administration (FDA) in 2009 for the treatment of CLL.
See Also
- Monoclonal antibodies
- Chronic lymphocytic leukemia
- CD20
- Antibody-dependent cellular cytotoxicity
- Complement-dependent cytotoxicity
This article is a immunology stub. You can help WikiMD by expanding it!
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
